# Debate Matchup Judgment Report

**Claude Sonnet 5 (high)** vs **Tencent Hy4 Preview (high)**

- Paired result: **Tie**
- Mean entertainment: `7.50 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Widespread adoption of continuous glucose monitors by non-diabetic people will improve public health more than it will fuel anxiety and over-medicalization.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0650__claude-sonnet-5-high__hy4-preview-high__s0__tpl_placement_active_20260813a.md): PRO = **Claude Sonnet 5 (high)**, CON = **Tencent Hy4 Preview (high)**
- [Debate B transcript](../../../transcripts/prop_0650__hy4-preview-high__claude-sonnet-5-high__s1__tpl_placement_active_20260813a.md): PRO = **Tencent Hy4 Preview (high)**, CON = **Claude Sonnet 5 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0650__claude-sonnet-5-high__hy4-preview-high__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **Claude Sonnet 5 (high)**, CON = **Tencent Hy4 Preview (high)**
- Judged result: Split `2-1` for **Tencent Hy4 Preview (high)**.
- Entertainment scores: `7`, `7`, `8`
- Mean signed raw margin (PRO+): `-0.93`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Kimi K2.6 | A = Claude Sonnet 5 (high) (PRO); B = Tencent Hy4 Preview (high) (CON) | Claude Sonnet 5 (high) | +1.2 | +1.36 | 7.0 |
| Muse Spark 1.1 (high) | A = Tencent Hy4 Preview (high) (CON); B = Claude Sonnet 5 (high) (PRO) | Tencent Hy4 Preview (high) | -1.5 | -1.59 | 7.0 |
| Qwen 3.7 Max | A = Claude Sonnet 5 (high) (PRO); B = Tencent Hy4 Preview (high) (CON) | Tencent Hy4 Preview (high) | -2.5 | -2.12 | 8.0 |

### Judge Notes

- **Kimi K2.6** (A = Claude Sonnet 5 (high) (PRO); B = Tencent Hy4 Preview (high) (CON)): Side A (PRO) won by maintaining that post-meal glucose damage operates on a physiological continuum that relative CGM feedback can mitigate without requiring a formal non-diabetic threshold. Its most decisive move was the asymmetry frame in Rebuttal 2: device cessation is a null, reversible outcome, whereas prevented insulin resistance is durable and compounding. CON effectively challenged interpretability and raised genuine over-medicalization risks, but never squarely overturned that weighing—its harms remained conditional and reversible against a concrete, compounding benefit.
  Most decisive rebuttal noted: A's Rebuttal 2 answering B's Pressure Question Q2 by framing quitting as a null outcome and continued use as durable prevention, a comparative weighing CON never successfully broke.
- **Muse Spark 1.1 (high)** (A = Tencent Hy4 Preview (high) (CON); B = Claude Sonnet 5 (high) (PRO)): CON won the decisive clash on detection. PRO's case required CGM to reliably catch early insulin resistance, but CON showed no validated non-diabetic threshold, confounders that break meal-vs-meal comparisons, and false reassurance. PRO never answered that in Rebuttal 2, and the "quit = null outcome" framing failed against persistent restrictive eating and engagement design. The reversible vs irreversible asymmetry collapsed without a solid detection premise.
  Most decisive rebuttal noted: A's Rebuttal 2 A1/A2 answer handling B's pressure - explaining why home BP has anchors (averaged, outcome-linked, confirmatory) while CGM for non-diabetics lacks them, and reconciling "real but noisy signal" vs "valid screening test," which directly neutralized PRO's threshold-free relative feedback claim.
- **Qwen 3.7 Max** (A = Claude Sonnet 5 (high) (PRO); B = Tencent Hy4 Preview (high) (CON)): Side B won by systematically dismantling Side A's core analogies and asymmetry arguments. While Side A argued that CGM anxiety is reversible and metabolic damage is not, Side B effectively demonstrated that commercial CGM apps gamify normal physiological noise without validated non-diabetic thresholds, leading to persistent psychological harms and false reassurance. Side B's distinction between validated BP monitoring and unanchored CGM data was decisive, exposing the flaws in Side A's "just take it off" defense and proving that widespread adoption would likely mistarget the worried-well rather than reliably prevent disease.
  Most decisive rebuttal noted: Side B's Rebuttal 2, where they directly answered Side A's pressure questions by clearly distinguishing BP's validated, outcome-linked thresholds from CGM's unanchored, app-driven gamification, effectively neutralizing Side A's central analogy and asymmetry claim.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0650__hy4-preview-high__claude-sonnet-5-high__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **Tencent Hy4 Preview (high)**, CON = **Claude Sonnet 5 (high)**
- Judged result: Unanimous `3-0` for **Claude Sonnet 5 (high)**.
- Entertainment scores: `8`, `7`, `8`
- Mean signed raw margin (PRO+): `-1.60`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Kimi K2.6 | A = Tencent Hy4 Preview (high) (PRO); B = Claude Sonnet 5 (high) (CON) | Claude Sonnet 5 (high) | -1.5 | -1.70 | 8.0 |
| Muse Spark 1.1 (high) | A = Claude Sonnet 5 (high) (CON); B = Tencent Hy4 Preview (high) (PRO) | Claude Sonnet 5 (high) | -1.8 | -1.91 | 7.0 |
| Qwen 3.7 Max | A = Tencent Hy4 Preview (high) (PRO); B = Claude Sonnet 5 (high) (CON) | Claude Sonnet 5 (high) | -1.5 | -1.27 | 8.0 |

### Judge Notes

- **Kimi K2.6** (A = Tencent Hy4 Preview (high) (PRO); B = Claude Sonnet 5 (high) (CON)): CON successfully established that PRO's public-health benefit relies on unvalidated glucose-curve patterns in non-diabetics with no clinical threshold, trial, or mechanism proving predictive value. PRO's admission that "no universal line is needed" conceded the over-medicalization core: apps must invent their own thresholds, converting normal metabolic variation into actionable alarm. CON's sharper weighing—immediate, certain psychological costs versus speculative downstream benefits—and devastating dismantling of the step-counter and blood-pressure analogies in Rebuttal 2 left PRO's prevention story without sufficient grounding to outweigh the scaled anxiety mechanism.
  Most decisive rebuttal noted: CON's second rebuttal ([B4.1]–[B4.5]), which exposed that PRO's "personal baseline" defense merely relocated the invented-threshold problem, distinguished glucose from validated trackers like step counters, and framed PRO's case as an unvalidated public bet.
- **Muse Spark 1.1 (high)** (A = Claude Sonnet 5 (high) (CON); B = Tencent Hy4 Preview (high) (PRO)): CON maintained the decisive threshold clash: no validated cut-off for non-diabetic glucose curves, so apps must invent their own, which is over-medicalization. PRO conceded "no universal line needed" and offered only directional nudges, leaving benefit speculative while anxiety/restrictive-eating costs are immediate and certain. CON also distinguished step-counters (clear direction) from glucose (ambiguous valence) to neutralize habituation claim, giving cleaner weighing for net harm.
  Most decisive rebuttal noted: A's Rebuttal 2 A1/A2 – personalized baseline still requires invented rules, baseline unstable, and unlike 120/80 or step counts glucose has no safe direction, making compulsive checking and restrictive eating foreseeable and turning PRO's "no cutoff needed" into a concession.
- **Qwen 3.7 Max** (A = Tencent Hy4 Preview (high) (PRO); B = Claude Sonnet 5 (high) (CON)): Side B wins by decisively attacking the core mechanism of Side A's case: the validity of CGM data for non-diabetics. Side B successfully argued that without a clinically validated threshold for healthy individuals, CGM data is unanchored noise that consumer apps will interpret with invented thresholds, driving anxiety and disordered eating (e.g., avoiding healthy carbs). While Side A offered a strong weighing mechanism (reversible anxiety vs. permanent averted disease), Side B undermined the benefit side of the scale by showing the "signal" is unvalidated. Side A's reliance on hypothetical "well-designed apps" and regulation weakened their case regarding the reality of widespread consumer adoption. Side B's pressure questions and follow-ups were exceptionally sharp. Side B receives a minor execution cost for a clipped opening, but it did not materially affect the substantive clash.
  Most decisive rebuttal noted: Side B's Rebuttal 2 A1, dismantling Side A's "personal baseline" defense by showing that defining a deviation from a personal baseline still requires an unvalidated, invented threshold for healthy populations.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0650`
- Side-swap group ID: `prop_0650__claude-sonnet-5-high__hy4-preview-high__tpl_placement_active_20260813a`
- Raw paired winner: **Tie**
- Mean normalized margin for Claude Sonnet 5 (high): `+0.42`
- Complete side swap: `yes`
- Included in ratings: `yes`
